Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phendimetrazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.51 |
| ▸ | SLC6A3 known ✓ | Q01959 | 5/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phendimetrazine SCHEMBL15064942 | 1.00 | HTR1A (1.00) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL598950 | 1.00 | HTR1A (1.00) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL344020 | 1.00 | HTR1A (1.00) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL678276 | 0.98 | HTR1A (0.96) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL678073 | 0.96 | HTR1A (0.93) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL160376 | 0.87 | HTR1A (0.75) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL160375 | 0.87 | HTR1A (0.75) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL29554688 | 0.87 | HTR1A (0.75) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL29353044 | 0.87 | HTR1A (0.75) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL4381184 | 0.87 | HTR1A (0.75) | HTR1ASLC6A2SLC6A3HTR2BADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8615 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4271674-B9 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-03-11 | — | — | EP | claimed |
| US-12570642-B2 | GLP-IR modulating compounds | GILEAD SCIENCES, INC. (US) | 2026-03-10 | — | — | US | claimed |
| US-20260056214-A1 | DIAGNOSING AND TREATING END-STAGE RENAL DISEASE (ESRD) IN OBESE SUBJECTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2026-02-26 | — | — | US | claimed |
| EP-4699609-A2 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| EP-4691554-A2 | GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260027139-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | VIVUS, INC. | 2026-01-29 | — | — | US | claimed |
| US-12497382-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-12-16 | — | — | US | claimed |
| US-12491325-B2 | Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity | APTARGROUP, INC. (US) | 2025-12-09 | — | — | US | claimed |
| EP-4271674-B3 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | claimed |
| WO-1995011034-A1 | COMPOSITION FOR WEIGHT REDUCTION CONTAINING EPHEDRINE AND A MINERAL SALT OR CHELATE | KEOWN WENDY J (US) | 1995-04-27 | — | — | WO | claimed |
| US-5288503-A | WATER-PERMEABLE DIFFUSION BARRIER OF POLYVINYL ALCOHOL | SRCHEM INCORPORATED (US) | 1994-02-22 | — | — | US | claimed |
| EP-0367746-B1 | Sustained release drug-resin complexes | RICHARDSON VICKS INC (US) | 1994-02-02 | — | — | EP | claimed |
| EP-0384514-B1 | Dual-action tablet | NORWICH EATON PHARMA (US) | 1993-11-24 | — | — | EP | claimed |
| US-5260066-A | Cryogel bandage containing therapeutic agent | SRCHEM INCORPORATED (US) | 1993-11-09 | — | — | US | claimed |
| US-5096712-A | METHOD FOR ENHANCING PERFORMANCE SO AS TO IMPROVE VIGOR AND DECREASE FATIGUE, CONFUSION, TENSION, AND ANXIETY | INTERNEURON PHARMACEUTICALS, INC. (US) | 1992-03-17 | — | — | US | claimed |
| US-5019594-A | Method for decreasing appetite | INTERNEURON PHARMACEUTICALS, INC. (US) | 1991-05-28 | — | — | US | claimed |
| US-4996047-A | Sustained release drug-resin complexes | RICHARDSON-VICKS, INC. (US) | 1991-02-26 | — | — | US | claimed |
| EP-0367746-A2 | Sustained release drug-resin complexes | RICHARDSON-VICKS, INC. (US) | 1990-05-09 | — | — | EP | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |